Exactech Inc. (NASDAQ:EXAC) shares hit a new 52-week high on Monday . The stock traded as high as $27.51 and last traded at $27.40, with a volume of 13,429 shares traded. The stock had previously closed at $27.12.

Several analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Exactech from a “buy” rating to a “hold” rating in a research report on Tuesday, June 28th. Robert W. Baird raised shares of Exactech from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $21.00 to $26.00 in a research report on Wednesday, April 13th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $23.25.

The stock has a market cap of $388.34 million and a PE ratio of 25.99. The firm’s 50 day moving average is $25.83 and its 200 day moving average is $21.50.

Exactech (NASDAQ:EXAC) last announced its earnings results on Tuesday, April 26th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.02. During the same period in the previous year, the firm posted $0.29 EPS. The firm earned $65.30 million during the quarter, compared to analyst estimates of $63.63 million. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. Equities analysts forecast that Exactech Inc. will post $1.17 EPS for the current year.

In related news, VP Betty A. Petty sold 18,000 shares of the business’s stock in a transaction dated Friday, April 29th. The shares were sold at an average price of $22.65, for a total value of $407,700.00. Following the completion of the transaction, the vice president now owns 70,400 shares of the company’s stock, valued at approximately $1,594,560. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Joel C. Phillips sold 3,900 shares of the business’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $23.13, for a total transaction of $90,207.00. Following the completion of the transaction, the chief financial officer now directly owns 100,632 shares of the company’s stock, valued at approximately $2,327,618.16. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently made changes to their positions in the company. Morgan Stanley increased its position in shares of Exactech by 6.3% in the fourth quarter. Morgan Stanley now owns 67,495 shares of the company’s stock valued at $1,225,000 after buying an additional 3,982 shares during the last quarter. Gabelli Funds LLC increased its position in shares of Exactech by 2.8% in the fourth quarter. Gabelli Funds LLC now owns 296,024 shares of the company’s stock valued at $5,373,000 after buying an additional 8,000 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Exactech by 6.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 557,024 shares of the company’s stock valued at $10,110,000 after buying an additional 34,863 shares during the last quarter. Finally, Gamco Investors INC. ET AL boosted its stake in Exactech by 1.5% in the fourth quarter. Gamco Investors INC. ET AL now owns 649,279 shares of the company’s stock valued at $11,784,000 after buying an additional 9,800 shares during the period.

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee implants, hip implants, biologics and spine, extremity implants and other products. Its other products segment includes surgical instruments, bone cement and other implant product lines.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.